Primary Prostatic Stromal Sarcoma on 18 F-PSMA PET/CT.

Area of Science:

• Oncology
• Radiology
• Urology

Background:

• Primary prostatic stromal sarcoma is an exceptionally rare malignancy.
• Serum prostate-specific antigen (PSA) levels are typically normal in these cases, complicating early diagnosis.

Observation:

• A case study involving a 23-year-old male with primary prostatic stromal sarcoma is presented.
• 18F-prostate-specific membrane antigen (PSMA) Positron Emission Tomography/Computed Tomography (PET/CT) revealed a prostate mass and multiple liver lesions with high PSMA uptake.

Findings:

• Chemotherapy resulted in a reduction of PSMA expression within the primary prostate tumor.
• The previously identified PSMA-avid liver lesions resolved following treatment.

Implications:

• This case highlights the utility of 18F-PSMA PET/CT in diagnosing and monitoring rare prostatic cancers.
• The findings suggest that PSMA expression can be a responsive biomarker to chemotherapy in prostatic stromal sarcoma.